GlaxoSmithKline files new pre-pandemic influenza vaccine in Europe

Armen Hareyan's picture

GlaxoSmithKline (GSK plc) today announced that its new generation H5N1 split antigen pre-pandemic influenza vaccine has been accepted for review by the Committee for Medicinal Products for Human Use (CHMP) in Europe. This innovative vaccine utilises GSK's novel proprietary adjuvant system technology which allows a very low amount of antigen (3.8

Share this content.

If you liked this article and think it may help your friends, consider sharing or tweeting it to your followers.